AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ...
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...
These shares are ending the week in the red. But why? For over a decade now, we've been helping Australian investors – just like you! – become more confident investors. And to help new investors get ...
Morning, y’all! Full moon tonight. Not just any full moon, but a full blood worm moon total lunar eclipse! Say that five times fast. Let’s get to it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results